Arheuma

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arheuma

Quick Facts

Property Description
Active ingredient Leflunomide
Form Film-coated tablet (Oral preparation)
Pharmacological class Conventional Synthetic DMARD (csDMARD)
General purpose Disease modification (Slowing chronic inflammation)
Origin Synthetic compound

What Type of Medicine is Arheuma? (Identity and Classification)

Arheuma is a prescription-only medicine (Rx) containing the active substance Leflunomide, which is classified as a Disease-Modifying Anti-Rheumatic Drug (DMARD). It is specifically categorized as a conventional synthetic DMARD (csDMARD), distinguished by its systemic effect as both an immunosuppressant and an immunomodulatory agent. As a systemic treatment intended for adults, Arheuma is intended to address the underlying immune activity across the entire body. The drug's classification indicates that it is designed to alter the course of chronic inflammatory diseases, rather than just provide symptomatic relief.

Leflunomide: Composition, Origin, and Form (Substance and Structure)

The core active ingredient in Arheuma is Leflunomide, a synthetic compound derived from the isoxazole chemical class. It is supplied as a single-ingredient product for the oral route, typically as a film-coated tablet. Leflunomide is administered as a prodrug, which means the molecule is biologically inactive until it is efficiently converted by the body into its pharmacologically potent substance, A77 1726. Pharmacological studies describe this unique metabolic activation pathway, which is essential for achieving the sustained therapeutic effect of the drug.

Arheuma's General Purpose as a DMARD (Core Therapeutic Goal)

The general therapeutic purpose of Arheuma is to modify the progression of chronic inflammatory diseases, aiming to slow structural damage. It functions as an anti-proliferative agent by interfering with a key metabolic pathway that specific immune cells, such as T-lymphocytes, need for rapid division. By controlling the inappropriate multiplication and activity of these inflammatory cells, Arheuma helps to limit the destructive effects of the underlying autoimmune response throughout the body, establishing sustained control over the chronic inflammation.

What side effects are possible with Arheuma?

Possible side effects and safety information

The regulatory safety profile for Arheuma (Leflunomide) is defined by officially documented adverse reactions and specific safety constraints established by government authorities like the FDA and EMA. The profile is characterized by a spectrum of events categorized by frequency and the organ system affected.

Key safety domains relate to the potential for Hepatotoxicity (liver damage) and Hematological Toxicity (blood disorders), which necessitate regular monitoring of liver enzymes and blood counts, as specified in regulatory labeling. Increases in liver enzymes are often noted as more frequent at the start of treatment or during dose escalation, although severe hepatic reactions, including hepatic failure, are classified as rare.

Classification Examples of Officially Listed Side Effects
Very Common (≥ 1/10) Diarrhea, headache, alopecia (hair thinning), hypertension, elevated liver enzymes.
Common (≥ 1/100 to < 1/10) Weight decrease, stomatitis, rash, leukopenia.

Serious adverse reactions documented in regulatory sources include the rare possibility of severe skin reactions (e.g., Stevens-Johnson syndrome) and interstitial lung disease (ILD), which is classified as very rare. Due to the long half-life of the active metabolite, adverse effects may occur or persist after treatment cessation.

Population-Specific Constraints: The medicine is formally contraindicated in patients with severe hepatic impairment, pre-existing significant hematological conditions, severe immunodeficiency states, and during pregnancy or lactation due to the high risk of fetal harm. The regulatory framework requires effective contraception during and for a specified time following treatment, or the implementation of an accelerated drug elimination (washout) procedure.

Overdose and Emergency Response

Overdose and when to seek help

Overdose may present with specific documented signs, including gastrointestinal distress (diarrhea, stomach pain), constitutional symptoms (extreme tiredness, weakness, pale skin), and cardiopulmonary changes (fast heartbeat and shortness of breath).

Regulatory documents identify that overdose or severe toxicity carries a risk of serious, life-threatening complications, particularly severe liver injury, including fatal liver failure, and severe cutaneous reactions such as Stevens-Johnson syndrome (SJS). Haematological toxicity, evidenced by changes in blood cell levels (leukopenia), is also a documented concern. Patients with pre-existing liver disease face the greatest risk of severe hepatic injury.

When to Seek Immediate Medical Help

Immediate emergency services must be contacted if the affected individual has collapsed, experienced a seizure, exhibits trouble breathing, or cannot be awakened, as stated in official labeling. Additionally, contacting a poison control center is a required action in cases of suspected overdose.

Official Management Procedure

As no specific antidote is known, regulatory guidance mandates an Accelerated Drug Elimination Procedure (washout) due to the prolonged half-life of the active metabolite. This procedure utilizes agents such as cholestyramine or activated charcoal to rapidly remove the substance from the body. Post-washout, continued monitoring of liver enzyme (ALT) and blood cell levels is required until normalization.

Therapeutic Uses of Arheuma

What Arheuma Treats: Main Uses and Benefits

Arheuma is commonly used across conditions presenting with systemic or localized discomfort, focusing on symptoms related to physical discomfort and noticeable physiological strain. The overall therapeutic goal is to provide support that contributes to easing the overall symptom load and may assist with maintaining functional stability.

This medication is relevant for managing symptoms that interfere with daily functioning across therapeutic domains where additional symptomatic support is needed. It may contribute to easing the overall symptom load in situations involving persistent joint stiffness, chronic pain, and restricted mobility. Arheuma is typically applied when supportive symptomatic assistance is needed during phases when symptoms become more noticeable, such as when groups of symptoms appear suddenly or intensify during a flare-up.

Quick Facts: Therapeutic Relevance

  • Symptom Domains: Used in situations involving certain distressing symptoms linked to inflammatory or irritative states.
  • Clinical Scenarios: Often used during phases when symptoms intensify and supportive relief is needed.
  • Patient Benefit: Provides support that helps ease the overall symptom burden and may assist with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Arheuma is officially indicated for the treatment of adult patients (aged 18 years and older) with certain chronic inflammatory conditions.

Contraindicated Populations

Official regulatory labels define specific groups for whom use is contraindicated and strictly prohibited:

  • Pregnancy and Lactation: The medicine is contraindicated in pregnant women and women who are breast-feeding. Women of childbearing potential must use reliable contraception during treatment and until plasma levels of the active metabolite are confirmed to be below 0.02 mg/L after cessation.
  • Hepatic Impairment: Patients with severe hepatic impairment or other severe impairment of liver function must not use this medicine. Those with pre-existing acute or chronic liver disease, or elevated liver enzymes (ALT > 2 x ULN) at baseline, are excluded.
  • Immune and Blood Disorders: Individuals with severe immunodeficiency states (e.g., AIDS) or significantly impaired bone marrow function (e.g., severe anemia or leucopenia) are contraindicated.
  • Hypersensitivity: Patients with known hypersensitivity to leflunomide, its metabolite teriflunomide, or any components of the tablet.

Age and Comorbidity Restrictions

  • Pediatric Use: Use in patients below 18 years of age is not recommended because efficacy and safety in this population have not been established by regulators.
  • Renal/Metabolic: The medicine is contraindicated in patients with severe hypoproteinaemia and those with moderate to severe renal insufficiency, primarily due to insufficient clinical experience available for these groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Arheuma (Leflunomide) has officially documented pharmacokinetic and pharmacodynamic interactions that affect the exposure of co-administered substances. The active metabolite, A77 1726, is documented as an inhibitor of the enzyme CYP2C8 and an inducer of CYP1A2, which alters the clearance of medicines metabolized by these pathways. The active metabolite also inhibits several drug transporters, including BCRP, OATP1B1/B3, and OAT3.

This interaction profile leads to specific regulatory constraints. Co-administration with Teriflunomide is formally contraindicated. Due to increased exposure resulting from transporter inhibition, co-administration with Rosuvastatin is subject to a regulatory-mandated maximum dose restriction of 10 mg once daily. Furthermore, the exposure of oral contraceptive components, such as Ethinylestradiol and Levonorgestrel, is officially documented to be increased.

Regarding substances, the consumption of alcohol is not recommended due to the potential for additive hepatotoxic effects. The extent of the drug’s absorption is officially stated as not affected by food. A population-specific restriction notes that Arheuma is contraindicated in patients with severe hepatic impairment due to the risk of heightened toxicity.

Mechanism of Action

Arheuma, as a prodrug, undergoes rapid metabolic conversion to its primary active metabolite, A77 1726 (teriflunomide). This metabolite functions predominantly as a non-competitive inhibitor of the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH). DHODH catalyzes a key step in the de novo pyrimidine synthesis pathway, specifically the conversion of dihydroorotate to orotate.

Inhibition of DHODH by A77 1726 limits the intracellular pool of uridine monophosphate (rUMP). Lymphocytes, particularly activated T-cells, exhibit a high metabolic dependence on the de novo pathway for pyrimidine synthesis to support rapid proliferation. The resulting reduction in ribonucleotide availability prevents these cells from progressing from the G1 phase to the S phase of the cell cycle, inducing G1 phase arrest and halting their clonal expansion. The action is cytostatic on these target cells. A secondary, less prominent interaction involves the antagonism of Protein-tyrosine kinase 2-beta (PTK2B), further modulating intracellular signaling pathways involved in cell activation and proliferation. The system-level consequence is a selective modulation of rapidly proliferating lymphocytes, resulting in a quantifiable decrease in their circulating numbers.

Dosage and Administration Information

How Arheuma is Used: Administration Guidelines

Arheuma (Leflunomide) is administered according to a specific regimen defined in prescribing information, focusing on the oral route and a structured dosing pattern over time.

Administration Overview

The medicine is supplied as a film-coated tablet and is taken orally. The tablets must be swallowed whole with sufficient liquid. Administration is permitted with or without food, as meals do not significantly alter drug absorption.

Treatment must be initiated and supervised by a specialist physician experienced in managing the conditions for which it is prescribed.


Dosing and Schedule

Arheuma is typically taken once daily. The regimen involves an optional initial period followed by a long-term maintenance dose, designed to achieve necessary therapeutic concentrations:

Feature Instruction Notes
Optional Loading Dose 100 mg once daily for three days May be used to reach steady-state concentration faster.
Standard Maintenance Dose 20 mg once daily The maximum recommended daily dose.
Lower Maintenance Dose 10 mg once daily Used if the 20 mg dose is not tolerated.

The loading dose is often omitted when starting treatment in certain patients to reduce the potential for adverse effects, with the specialist initiating the 20 mg maintenance dose immediately.

Duration and Specific Populations

Arheuma is intended for long-term use. Therapeutic effects typically become apparent after four to six weeks of consistent daily use and may continue to improve for up to six months.

No dose adjustment is required for older adults (65 years and above) or for patients with mild renal impairment. The medicine is not recommended for use in pediatric patients (under 18 years of age).

Recent Clinical Evidence

Arheuma: Recent Clinical Evidence

Research has explored the effects of Arheuma (leflunomide) in conditions such as rheumatoid arthritis (RA) and other autoimmune diseases. Clinical trials and meta-analyses focus on its ability to help manage disease activity and potentially slow disease progression when used as a disease-modifying antirheumatic drug (DMARD).

Efficacy in Rheumatoid Arthritis

Multiple randomized controlled trials (RCTs) have investigated the outcomes of Arheuma therapy in adults with active RA. Study outcomes are often measured using composite tools like the ACR20 response (a 20% improvement across specified disease activity measures) and the Disease Activity Score 28 (DAS28).

  • Monotherapy: In key Phase III trials, a significantly higher proportion of patients receiving Arheuma met the ACR20 response criteria compared to those receiving placebo. Response rates, such as ACR20, ACR50, and ACR70, were consistently observed to be higher across various time points.
  • Combination Therapy: Studies have also examined its use in combination with other DMARDs. Evidence suggests that in patients with an incomplete response to methotrexate alone, adding Arheuma to the regimen was associated with greater improvements in disease activity scores.

Safety Profile and Adverse Events

The safety profile of Arheuma has been well-documented across trials and post-marketing surveillance. The drug is generally considered to have a manageable safety profile in the context of long-term DMARD use.

Type of Adverse Event Frequency in Clinical Trials (Commonly Reported)
Gastrointestinal Diarrhea, Nausea, Abdominal Pain
Dermatological Rash, Alopecia (Hair Loss)
Hepatic (Liver) Elevated liver enzymes (ALT/AST)
Other Headache, Upper Respiratory Tract Infection

Serious adverse events are also monitored, including serious infections and certain hematological (blood) conditions. Due to the potential for liver enzyme elevation, blood tests are typically required for monitoring during therapy. Patients should consult their specialist regarding the full safety profile and the required monitoring schedule.

Key Studies & References

  1. Comparison of leflunomide and methotrexate in patients with active rheumatoid arthritis of recent onset: a randomized, multicenter, double-blind trial.
  2. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
  3. National Institute for Health and Care Excellence (NICE) Guideline: Rheumatoid arthritis in adults: management

Frequently Asked Questions (FAQ)

Common questions about Arheuma (FAQ)

Q: Can Arheuma cause issues with the liver?

Official regulatory documents indicate that Arheuma may cause elevated liver enzymes and, in rare instances, severe liver injury, including liver failure. Due to this potential, regular monitoring of liver enzyme levels through blood tests is specified in regulatory guidelines throughout the course of treatment.

Q: What should I know about taking Arheuma with common over-the-counter painkillers?

Official product information describes that Arheuma has the potential for additive hepatotoxic effects when taken alongside other substances that can damage the liver, which can include certain over-the-counter painkillers. Official documentation encourages discussion with a specialist regarding all co-administered medications.

Q: Do I need to avoid any specific foods or drinks while using Arheuma?

According to official regulatory sources, the consumption of alcohol is not recommended because of the potential for an increased risk of liver toxicity. Separately, the drug's absorption is officially stated as not affected by food, meaning it can be taken with or without a meal.

Q: Is Arheuma safe to use if I have an existing heart condition?

Official information lists hypertension (high blood pressure) as a very common side effect of Arheuma, and regulatory sources state that blood pressure should be monitored regularly. The primary warnings do not list direct contraindications for non-hypertensive heart diseases. Any pre-existing heart condition requires specialist review, as is customary.

Q: What should I do if I notice a change in my skin after starting Arheuma?

The official product labeling warns that serious, rare side effects such as severe skin reactions (e.g., Stevens-Johnson syndrome) have been documented. Regulatory documents state that patients should inform their health care provider if they develop a new rash or experience other skin changes.

Q: Does Arheuma interact with medications for high blood pressure?

Regulatory sources note that Arheuma itself can cause hypertension as an adverse reaction, which is why blood pressure monitoring is necessary. Specific drug interactions with most blood pressure-lowering medicines are not uniformly noted in the primary product warnings, but all co-administered medications are subject to review by a specialist.

Q: How should I store Arheuma at home?

The medicine should be stored at room temperature, typically between 15 C and 30 C (59 F and 86 F). It is essential to protect the medication from light and moisture and keep it in its original, tightly closed container.

Q: Does Arheuma replace pain medication?

Arheuma is classified as a Disease-Modifying Anti-Rheumatic Drug (DMARD). This classification means its purpose is to address the underlying immune activity that drives chronic inflammatory diseases, aiming to slow structural damage over time, rather than providing immediate pain relief.

Q: Is Arheuma the same type of drug as [Specific Competitor Drug]?

Arheuma is classified as a conventional synthetic DMARD (csDMARD). It contains the active substance Leflunomide, which works by inhibiting a specific enzyme called DHODH. This pharmacological classification is the factual basis for general comparison with other drugs.

Q: What is the typical age range of people who use Arheuma?

Official labeling indicates that Arheuma is intended for the treatment of adult patients aged 18 years and older. Regulatory information also specifies that no dose adjustment is required for older adults who are 65 years and above.

Q: What happens if I miss a dose of Arheuma? (Informational only)

The guidance in patient information states that a missed dose should not be doubled when the next scheduled dose is taken. The patient continues with the next scheduled maintenance dose.

Q: Can Arheuma affect mood or cause anxiety?

Official regulatory lists of common and very common side effects typically focus on events related to the gastrointestinal system, liver, skin, and blood. Mood changes or anxiety are not generally listed among the most frequently reported adverse reactions.

Q: Will Arheuma stop working after a period of time?

Clinical experience and trials described in official regulatory documents support the use of Arheuma as a long-term treatment option for chronic inflammatory diseases. Regulatory sources do not mention a mandatory cessation date due to loss of effectiveness over time.

Q: What if Arheuma doesn't seem to be working for my condition?

Official sources describe that therapeutic effects typically require time and may only become apparent after four to six weeks of consistent daily use. If an expected response is not achieved after this initial period, a specialist may consider adjusting the treatment regimen.

Q: Can people with diabetes use Arheuma?

Official regulatory documents do not list diabetes as a formal contraindication for using Arheuma. However, warnings mention a potential association between diabetes and an increased risk for side effects such as peripheral neuropathy (nerve damage in the extremities), as indicated in official product information.

Q: Is Arheuma available in different strengths or forms?

Arheuma (Leflunomide) is supplied as film-coated tablets for oral use. These tablets are typically available in multiple strengths, which often include 10 mg and 20 mg.

Q: How does Arheuma differ from traditional anti-inflammatory drugs?

Arheuma is classified as a Disease-Modifying Anti-Rheumatic Drug (DMARD). This means it works systemically by modulating the underlying immune system and modifying the disease course, unlike traditional anti-inflammatory drugs which primarily focus on symptomatic pain and swelling relief.

Q: Are there any specific vaccines I should avoid while on Arheuma?

Regulatory documents state that because Arheuma is an immunosuppressive agent, the use of live vaccines is generally not recommended for patients while they are receiving this medication.

Q: What are the common reasons a doctor might stop prescribing Arheuma?

Reasons for cessation detailed in official warnings include confirmed pregnancy, the development of severe liver injury (hepatic failure), signs of severe hematological toxicity (blood disorders), or the occurrence of serious side effects such as interstitial lung disease (ILD).

Q: Does Arheuma impact fertility or reproductive health?

Official documents impose strict requirements for reliable contraception for women of childbearing potential during and for a specified time after treatment, due to the high risk of fetal harm. Specific regulatory statements regarding a primary impact on fertility are not the focus of the current warnings.

Q: Why is Arheuma sometimes used for conditions other than [Main Use]? (Clarification, not off-label advice)

The official labeling will list all approved indications for which the drug has been formally reviewed and authorized by regulatory bodies. Any use for conditions not listed in this official therapeutic indications section is considered outside the labeled use.

How should Arheuma be stored and disposed of?

Storage and Disposal Requirements

Arheuma (leflunomide) film-coated tablets must be stored according to mandatory regulatory guidelines to maintain product integrity.

Scope Area Official Regulatory Statement
Storage Temperature Store at room temperature, typically between 15 C and 30 C (59 F and 86 F), and not above 25 C in some regions.
Protection Requirements Keep in a dry place and protect from light and heat. Keep from freezing.
Container Rules Store the medicine in its original package or a tightly closed container.
Disposal Instructions Do not keep outdated medicine. Ask a healthcare professional or pharmacist how to dispose of any unused or expired product. Disposal must be in accordance with local requirements and may involve a special waste collection point.
Child Protection Keep the medicine and all containers out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arheuma found in:

A-Z Index: